Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Perspectives in Diabetes

Neuronal Glucosensing

What Do We Know After 50 Years?

  1. Barry E. Levin12,
  2. Vanessa H. Routh3,
  3. Ling Kang2,
  4. Nicole M. Sanders4 and
  5. Ambrose A. Dunn-Meynell12
  1. 1Neurology Service, Department of Veterans Affairs New Jersey Health Care System, East Orange, New Jersey
  2. 2Department of Neurology and Neurosciences, New Jersey Medical School, University of Medicine and Dentistry, Newark, New Jersey
  3. 3Department of Pharmacology and Physiology, New Jersey Medical School, University of Medicine and Dentistry, Newark, New Jersey
  4. 4Metabolism/Endocrinology Service, VA Puget Sound Health Care System, Seattle, Washington
  1. Address correspondence and reprint requests to Barry E. Levin, MD, Neurology Service (127C), Department of Veterans Affairs NJ Health Care System, 385 Tremont Ave., E. Orange, NJ 07018-1095. E-mail: levin{at}umdnj.edu
Diabetes 2004 Oct; 53(10): 2521-2528. https://doi.org/10.2337/diabetes.53.10.2521
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

What Do We Know After 50 Years?

Abstract

Glucosensing neurons are specialized cells that use glucose as a signaling molecule to alter their action potential frequency in response to variations in ambient glucose levels. Glucokinase (GK) appears to be the primary regulator of most neuronal glucosensing, but other regulators almost certainly exist. Glucose-excited neurons increase their activity when glucose levels rise, and most use GK and an ATP-sensitive K+ channel as the ultimate effector of glucose-induced signaling. Glucose-inhibited (GI) neurons increase their activity at low glucose levels. Although many use GK, it is unclear what the final pathway of GI neuronal glucosensing is. Glucosensing neurons are located in brain sites and respond to and integrate a variety of hormonal, metabolic, transmitter, and peptide signals involved in the regulation of energy homeostasis and other biological functions. Although it is still uncertain whether daily fluctuations in blood glucose play a specific regulatory role in these physiological functions, it is clear that large decreases in glucose availability stimulate food intake and counterregulatory responses that restore glucose levels to sustain cerebral function. Finally, glucosensing is altered in obesity and after recurrent bouts of hypoglycemia, and this altered sensing may contribute to the adverse outcomes of these conditions. Thus, although much is known, much remains to be learned about the physiological function of brain glucosensing neurons.

  • ARC, hypothalamic arcuate nucleus
  • CSF, cerebrospinal fluid
  • GE, glucose excited
  • GI, glucose inhibited
  • GK, glucokinase
  • KATP channel, ATP-sensitive K+ channel
  • LDH, lactate dehydrogenase
  • MCT, monocarboxylate
  • NPY, neuropeptide Y
  • POMC, proopiomelanocortin
  • SGLT, sodium-glucose–linked glucose transporter
  • VMH, ventromedial hypothalamus
  • VMN, ventromedial hypothalamic nucleus

Footnotes

    • Accepted July 7, 2004.
    • Received May 3, 2004.
  • DIABETES
View Full Text
PreviousNext
Back to top

In this Issue

October 2004, 53(10)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Neuronal Glucosensing
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Neuronal Glucosensing
Barry E. Levin, Vanessa H. Routh, Ling Kang, Nicole M. Sanders, Ambrose A. Dunn-Meynell
Diabetes Oct 2004, 53 (10) 2521-2528; DOI: 10.2337/diabetes.53.10.2521

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Neuronal Glucosensing
Barry E. Levin, Vanessa H. Routh, Ling Kang, Nicole M. Sanders, Ambrose A. Dunn-Meynell
Diabetes Oct 2004, 53 (10) 2521-2528; DOI: 10.2337/diabetes.53.10.2521
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • GLUCOSENSING NEURONS INTEGRATE A VARIETY OF TIME- AND CONCENTRATION-DEPENDENT PATTERNS OF GLUCOSE CHANGE
    • HOW IS GLUCOSE SENSED?
    • GLUCOSENSING NEURONS AS METABOLIC SENSORS
    • WHAT PHYSIOLOGICAL FUNCTIONS ARE REGULATED BY GLUCOSENSING NEURONS?
    • HOW IS GLUCOSENSING ALTERED BY DISEASE?
    • SUMMARY AND CONCLUSIONS: WHAT HAVE WE LEARNED AND WHAT REMAINS TO BE LEARNED?
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Regulation of Hepatic Metabolism and Cell Growth by the ATF/CREB Family of Transcription Factors
  • Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes
  • Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders
Show more Perspectives in Diabetes

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.